Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure

NANot yet recruitingINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
PROCEDURE

Drug-eluting beads bronchial arterial chemoembolization

"Drug-eluting beads bronchial arterial chemoembolization generally uses platinum-containing two-drug chemotherapy platinum (cisplatin, carboplatin, nedaplatin) combined treatment, and drug-loaded microspheres can be loaded with vinorelbine, gemcitabine, irinote Kang, raltitrexed. The dose of chemotherapy drugs is set to 75mg/m2 of platinum, and the dose of chemotherapy through catheter infusion is reduced by 25%. The dose of drug-loaded drugs is vinorelbine 25mg/m2, gemcitabine generally 1000mg/m2, irinotecan 80mg/ m2, raltitrexed 4mg. Chemotherapy was perfused first, followed by embolization with drug-loaded microspheres, until the blood flow in the artery supplying the tumor slowed down and approached stagnation. The number of DEB-BACE treatments is determined by the investigator, and is given as needed according to the patient's condition, usually 1-2 times, with an interval of 28±10 days."

DRUG

Programmed Cell Death Protein 1 Inhibitor

Programmed cell death protein 1 inhibitor fixation was treated with sintilimab (Xinda Biopharmaceutical Co., Ltd.). It is administered by intravenous infusion, and the recommended dose is 200 mg, given once every 21 days. The medication will last for two years until disease progression or intolerable toxicity occurs. During immunotherapy, immunosuppressive agents will not be replaced and the dose will not be adjusted.

All Listed Sponsors
collaborator

Jiangxi Provincial Cancer Hospital

OTHER

collaborator

Jiangxi Chest Hospital

UNKNOWN

collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

collaborator

Zhejiang University

OTHER

lead

The Central Hospital of Lishui City

OTHER

NCT05248022 - Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure | Biotech Hunter | Biotech Hunter